Relaxation of Prescription-Drug Advertising Rules

The relaxation of prescription-drug advertising rules was one element in the expanding pharmaceutical marketplace that surrounded OxyContin’s introduction. By easing restrictions on detailed television advertisements making specific medical claims for nonnarcotic drugs, the change occurred amid a wider turn toward aggressive promotion and a pill-centered vision of treatment. The book’s account shows how commercial messaging met new medical standards for pain assessment, while leaving basic questions about how pain should be measured and treated unresolved.

Regulatory and Commercial Context

Around the time a police informant in Big Stone Gap was speaking with an officer, the FDA loosened rules on pharmaceutical advertising. The change allowed drugmakers to air detailed television advertisements touting specific medical claims for nonnarcotic medicines; the book does not describe it as permission to advertise OxyContin on television. More broadly, advertising spending rose from $360 million in 1995 to $1.3 billion in 1998, while pharmaceutical companies increasingly used gifts and other promotional tactics to reach doctors. With few industry or federal guidelines governing prescription-drug promotion, these strategies helped advance the idea that a pill could address nearly every ill and encouraged some patients to seek medicines they did not need.

OxyContin’s launch in 1996 took place within that increasingly promotional environment. Purdue Pharma promoted the drug through a large sales force and targeted doctors according to their prescribing potential. The company used data purchased from IMS Health to identify physicians who prescribed competing painkillers such as Percocet and Vicodin; doctors ranked as more promising prospects received more visits from representatives, sometimes bearing branded reminders such as clocks for examination rooms. Purdue’s sales staff was expected to make more than a million annual calls on doctors in hospitals and offices, including family physicians, and to promote OxyContin for noncancer pain as well as cancer pain.

Claims About Safety and Pain Treatment

Purdue Pharma’s marketing relied on claims that OxyContin was safe and reliable when used as prescribed. David Haddox, a pain specialist who became the company’s principal public advocate for the drug, presented addiction rates as below one percent. The company also taught doctors that doctor-caused addiction was exceptionally rare. These assurances supported a broad promotional message: prescribing OxyContin for conditions including back injuries and other moderate pain could be framed as responsible and compassionate care, rather than a practice requiring exceptional caution.

That message coincided with a shift in medical practice toward treating pain as the fifth vital sign, alongside blood pressure, heart rate, respiratory rate, and temperature. Hospitals and doctors increasingly relied on patient-satisfaction surveys, including those conducted by Press Ganey, and competed for high scores that could affect reimbursements. In 1999, the Joint Commission on Accreditation of Healthcare Organizations approved mandatory standards for assessing and treating pain. The standards responded to a real concern that pain had long been undertreated, but they also gave Purdue an opening to position itself as a resource for institutions seeking to comply.

Institutional Standards and Commercial Opportunity

Purdue’s budget planning treated the new standards as a business opportunity. The company anticipated that it could gain standing as a leader in pain management by helping hospitals meet accreditation requirements, and planned branded materials for clinical settings: $300,000 worth of scroll pens, $225,000 worth of resource binders, and $290,000 worth of wall charts and clipboards promoting pain as the fifth vital sign. The scale and specificity of these plans show how a medical framework could become a channel for product marketing, with corporate branding placed alongside institutional efforts to improve pain care.

The book sets this campaign against broader concern that patients were receiving inadequate relief. A 2000 article in The New York Times described an older nursing-home resident with severe osteoporosis and pulmonary disease who had been given only Tylenol. Such cases strengthened the case for taking pain seriously, but the goal of adequate relief remained undefined. The tension was not simply between treating pain and ignoring it: the same call for better care could be translated into more prescribing without a reliable measure of which treatment would help a particular patient.

Measurement, Prescribing, and Consequences

Pain scales offered a simple way to standardize assessment, but the apparent precision concealed the subjective nature of the measure. A person’s reported score could place the pain of labor and that of a stubbed toe at the same level, depending on individual tolerance. Experts later acknowledged that numerical assessment was objective only in appearance, and that reliance on pain scales did not correspond to improved patient outcomes. The book links this system, alongside expanding opioid promotion, to increased opioid prescribing and abuse.

John Burton, head of emergency medicine at Carilion Clinic, recalled that physicians had been urged to make pain a higher priority. He later recognized that his own confidence that a two-week supply of opioid pills could not lead to dependence had been wrong. His account gives the policy and marketing history a clinical consequence: pressure to respond more seriously to pain operated in settings where doctors lacked a full understanding of the risks and effects of their prescribing. The book presents relaxed advertising rules, Purdue’s sales strategy, and new pain-assessment standards as interlocking parts of a larger history, not as a single explanation for the opioid crisis.